GB1254466A - Pharmaceutical methods and compositions - Google Patents

Abstract

1,254,466. Polyphosphonates. PROCTER & GAMBLE CO. 11 Dec., 1968 [11 Dec., 1967; 1 April, 1968], No. 58822/68. Heading A5B. Animals other than humans are treated for conditions involving pathological calcification or hard tissue demineralization by administering internally thereto one or more polyphosphonates of the formulae: in which R 1 and R 2 are each H or -CH 2 OH; n is an integer from 3 to 10; R 3 is H, alkyl, cycloalkyl, alkenyl, aryl, phenethenyl, benzyl, halogen, amino, substituted a m i n o , -CH 2 COOH, -CH 2 PO 3 H 2 , -CH(PO 3 H 2 ) (OH) or -CH 2 CH (PO 3 H 2 ) 2 and R, is H, alkyl, amino, benzyl, halogen, -OH, or a pharmaceutically acceptable salt thereof alone or in admixture with a pharmaceutically acceptable carrier. Suitable salts include alkali metal (e.g. Na, K), alkaline earth metal (e.g. Ca, Mg), non-toxic heavy metal (e.g. Sn, In), ammonium and substituted ammonium (e.g. mono-, di- and triethanolammonium) salts. Ethane-1-hydroxy-1, 1 diphosphonic acid (also known as 1-hydroxyethylidene diphosphonic acid) is the preferred active compound. The polyphosphonates may be incorporated in animal feeds, concentrates and supplements, which may also contain vitamins, minerals, antibiotics, steroids, trace elements, anthelmintics and other medicaments or growth-stimulating substances. The polyphosphonates may also be administered orally, parenterally or rectally in unit dosage forms comprising tablets, suppositories, pills, dragees, wrapped powders, cachets, sachets, capsules, ampoules or granules.